---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-025228"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2022-11-16T23:59:59+00:00"
generated_at: "2026-06-21T17:40:35.088117+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Surrozen pauses SZN-1326 Phase 1 trial due to liver enzyme elevations; Q3 net loss $13.4M

## Summary
- Voluntarily paused SZN-1326 Phase 1 SAD trial after grade 3 ALT/AST elevations in 3 subjects; transaminases resolved spontaneously.
- SZN-043 Phase 1 ongoing but with grade 1-2 transaminase elevations; re-evaluating timeline.
- Entered partnership with Boehringer Ingelheim for SZN-413; upfront $12.5M, milestones up to $586.5M plus royalties.
- Q3 2022 cash $78.4M (down from $92.7M in Q2); R&D expense $8.6M, net loss $13.4M.

## SEC filing metadata
- accession: 0000950170-22-025228
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2022-11-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017022025228/0000950170-22-025228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017022025228/srzn-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-025228
- JSON: https://secwatch.observer/filing/0000950170-22-025228.json
- Plain text: https://secwatch.observer/filing/0000950170-22-025228.txt

## Key facts
- Earnings Releases
  Surrozen, Inc./DE reported the quarter ended September 30, 2022 results: net income $13.4 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $13.4 million
  - Result: reported results
  source text: Net loss for the third quarter ended September 30, 2022 was $13.4 million, as compared to $14.0 million for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824893/000095017022025228/0000950170-22-025228-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.